New combo therapy targets tough lymphoma in early trial
NCT ID NCT06249191
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding mosunetuzumab, an antibody that helps the immune system attack cancer, to standard chemotherapy can safely treat aggressive B-cell lymphomas. About 30 adults with untreated high-grade or diffuse large B-cell lymphoma will receive the combination. Researchers will monitor side effects and check if tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mosunetuzumab (a monoclonal antibody) combined with chemotherapy (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone)
What this could lead to
If successful, this combination could offer a more effective first-line treatment for aggressive B-cell lymphomas, potentially improving remission rates.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. The combination may cause serious side effects like cytokine release syndrome or nerve toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact